Evidence map›Paper›PMID 38378650›Full record

ArticleGenes and environment : the official journal of the Japanese Environmental Mutagen Society2024

Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMice.

Takako Iso, Kenichiro Suzuki, Yasumasa Murata, Nozomu Hirose, Takaaki Umano, Katsuyoshi Horibata, Kei-Ichi Sugiyama, Akihiko Hirose, Kenichi Masumura, Mariko Matsumoto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes and environment : the official journal of the Japanese Environmental Mutagen Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Takako IsoDivision of Risk Assessment, National Institute of Health Sciences, Kanagawa, Japan.
Kenichiro SuzukiGenotoxicology Laboratory, BioSafety Research Center Inc., Shizuoka, Japan.
Yasumasa MurataDivision of Risk Assessment, National Institute of Health Sciences, Kanagawa, Japan.
Nozomu HiroseDivision of Risk Assessment, National Institute of Health Sciences, Kanagawa, Japan.
Takaaki UmanoDivision of Risk Assessment, National Institute of Health Sciences, Kanagawa, Japan.
Katsuyoshi HoribataDivision of Genetics and Mutagenesis, National Institute of Health Sciences, Kanagawa, Japan.
Kei-Ichi SugiyamaDivision of Genetics and Mutagenesis, National Institute of Health Sciences, Kanagawa, Japan.
Akihiko HiroseDivision of Risk Assessment, National Institute of Health Sciences, Kanagawa, Japan.
Kenichi MasumuraDivision of Risk Assessment, National Institute of Health Sciences, Kanagawa, Japan.
Mariko MatsumotoDivision of Risk Assessment, National Institute of Health Sciences, Kanagawa, Japan. mariko@nihs.go.jp.ORCID http://orcid.org/0000-0003-3976-6081
National Institute of Health Sciences · JPNational Institute of Health Sciences · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarbendazim (methyl 2-benzimidazolecarbamate, CASRN: 10605-21-7) exhibits spindle poisoning effects and is widely used as a fungicide. With respect to genotoxicity, carbendazim is deemed to be non-mutagenic in vitro, but it causes indicative DNA damage in vivo and chromosome aberrations in vitro and in vivo. In this study, we examined the mutagenicity of carbendazim in vivo.

resultsMutaMice were treated with carbendazim orally at doses of 0 (corn oil), 250, 500, and 1,000 mg/kg/day once a day for 28 days. A lacZ assay was used to determine the mutant frequency (MF) in the liver and glandular stomach of mice. MutaMice were administered up to the maximum dose recommended by the Organization for Economic Co-operation and Development Test Guidelines for Chemicals No. 488 (OECD TG488). The lacZ MFs in the liver and glandular stomach of carbendazim-treated animals were not significantly different from those in the negative control animals. In contrast, positive control animals exhibited a significant increase in MFs in both the liver and glandular stomach.

conclusionsCarbendazim is non-mutagenic in the liver and glandular stomach of MutaMice following oral treatment.

Indexed as

CarbendazimIn vivo mutagenicityTransgenic rodent gene mutation assay

Identifiers

PMID38378650
PMCPMC10877847
OpenAlexW4391971172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.